Kind of hard to do long term studies on people at the end of their lives, not to mention cognitive improvement when it is still spotty. By which I mean there is a long period in dementia when there are good times and bad times in memory and cognition, so while the whole trend is down, on a short scale it isn't so apparent. This drug sounds as promising as Remdisvir.
"In a trial called Emerge, patients who got the highest dose of aducanumab experienced a 22% improvement on a clinical dementia scale over placebo after 78 weeks, the company said. Yet the same patient group in the Engage study did worse than placebo patients on that same measure, as well as on a test of cognitive function."
Kind of hard to do long term studies on people at the end of their lives, not to mention cognitive improvement when it is still spotty. By which I mean there is a long period in dementia when there are good times and bad times in memory and cognition, so while the whole trend is down, on a short scale it isn't so apparent. This drug sounds as promising as Remdisvir.
"In a trial called Emerge, patients who got the highest dose of aducanumab experienced a 22% improvement on a clinical dementia scale over placebo after 78 weeks, the company said. Yet the same patient group in the Engage study did worse than placebo patients on that same measure, as well as on a test of cognitive function."